|
1
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Meacham CE and Morrison SJ: Tumour
heterogeneity and cancer cell plasticity. Nature. 501:328–337.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dick JE and JE D: Stem cell concepts renew
cancer research. Blood. 112:4793–4807. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen X, Rycaj K, Liu X and Tang DG: New
insights into prostate cancer stem cells. Cell Cycle. 12:579–586.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Skibinski A and Kuperwasser C: The origin
of breast tumor heterogeneity. Oncogene. 475:1–8. 2015.
|
|
6
|
Triscott J, Rose Pambid M and Dunn SE:
Concise review: Bullseye: Targeting cancer stem cells to improve
the treatment of gliomas by repurposing disulfiram. Stem Cells.
33:1042–1046. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zeki SS, Graham TA and Wright NA: Stem
cells and their implications for colorectal cancer. Nat Rev
Gastroenterol Hepatol. 8:90–100. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu CWLC, Li CH, Peng YJ, Cheng YW, Chen
HW, Liao PL, Kang JJ and Yeng MH: Snail regulates Nanog status
during the epithelial-mesenchymal transition via the
Smad1/Akt/GSK3β signaling pathway in non-small-cell lung cancer.
Oncotarget. 5:3880–3894. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang D, Lu P, Zhang H, Luo M, Zhang X, Wei
X, Gao J, Zhao Z and Liu C: Oct-4 and Nanog promote the
epithelial-mesenchymal transition of breast cancer stem cells and
are associated with poor prognosis in breast cancer patients.
Oncotarget. 5:10803–10815. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iv Santaliz-Ruiz LE, Xie X, Old M, Teknos
TN and Pan Q: Emerging role of nanog in tumorigenesis and cancer
stem cells. Int J Cancer. 135:2741–2748. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kregel S, Szmulewitz RZ and Vander Griend
DJ: The pluripotency factor Nanog is directly upregulated by the
androgen receptor in prostate cancer cells. Prostate. 74:1530–1543.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Loh YH, Wu Q, Chew JL, Vega VB, Zhang W,
Chen X, Bourque G, George J, Leong B, Liu J, et al: The Oct4 and
Nanog transcription network regulates pluripotency in mouse
embryonic stem cells. Nat Genet. 38:431–440. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Miyazawa K, Tanaka T, Nakai D, Morita N
and Suzuki K: Immunohistochemical expression of four different stem
cell markers in prostate cancer: High expression of NANOG in
conjunction with hypoxia-inducible factor-1α expression is involved
in prostate epithelial malignancy. Oncol Lett. 8:985–992.
2014.PubMed/NCBI
|
|
14
|
Kumazawa S, Kajiyama H, Umezu T, Mizuno M,
Suzuki S, Yamamoto E, Mitsui H, Sekiya R, Shibata K and Kikkawa F:
Possible association between stem-like hallmark and radioresistance
in human cervical carcinoma cells. J Obstet Gynaecol Res.
40:1389–1398. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu XF, Yang WT, Xu R, Liu JT and Zheng
PS: Cervical cancer cells with positive Sox2 expression exhibit the
properties of cancer stem cells. PLoS One. 9:e870922014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shen L, Huang X, Xie X, Su J, Yuan J and
Chen X: High expression of SOX2 and OCT4 indicates radiation
resistance and an independent negative prognosis in cervical
squamous cell carcinoma. J Histochem Cytochem. 62:499–509. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang L, Guo H, Lin C, Yang L and Wang X:
Enrichment and characterization of cancer stem like cells from a
cervical cancer cell line. Mol Med Rep. 9:2117–2123.
2014.PubMed/NCBI
|
|
18
|
Khokha MK, Hsu D, Brunet LJ, Dionne MS and
Harland RM: Gremlin is the BMP antagonist required for maintenance
of Shh and Fgf signals during limb patterning. Nat Genet.
34:303–307. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Church RH, Krishnakumar A, Urbanek A,
Geschwindner S, Meneely J, Bianchi A, Basta B, Monaghan S, Elliot
C, Strömstedt M, et al: Gremlin 1 preferentially binds to bone
morphogenetic protein-2 (BMP-2) and BMP-4 over BMP-7. Biochem J.
466:55–68. 2015. View Article : Google Scholar
|
|
20
|
Wang RN, Green J, Wang Z, Deng Y, Qiao M,
Peabody M, Zhang Q, Ye J, Yan Z, Denduluri S, et al: Bone
morphogenetic protein (BMP) signaling in development and human
diseases. Genes Dis. 1:87–105. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ducy P and Karsenty G: The family of bone
morphogenetic proteins. Kidney Int. 57:2207–2214. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ciuclan L, Sheppard K, Dong L, Sutton D,
Duggan N, Hussey M, Simmons J, Morrell NW, Jarai G, Edwards M, et
al: Treatment with anti-gremlin 1 antibody ameliorates chronic
hypoxia/SU5416-induced pulmonary arterial hypertension in mice. Am
J Pathol. 183:1461–1473. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Worthley DL, Churchill M, Compton JT,
Tailor Y, Rao M, Si Y, Levin D, Schwartz MG, Uygur A, Hayakawa Y,
et al: Gremlin 1 identifies a skeletal stem cell with bone,
cartilage, and reticular stromal potential. Cell. 160:269–284.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Karagiannis GS, Musrap N, Saraon P, Treacy
A, Schaeffer DF, Kirsch R, Riddell RH and Diamandis EP: Bone
morphogenetic protein antagonist gremlin-1 regulates colon cancer
progression. Biol Chem. 396:163–183. 2015. View Article : Google Scholar
|
|
25
|
Karagiannis GS, Treacy A, Messenger D,
Grin A, Kirsch R, Riddell RH and Diamandis EP: Expression patterns
of bone morphogenetic protein antagonists in colorectal cancer
desmoplastic invasion fronts. Mol Oncol. 8:1240–1252. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mulvihill MS, Kwon YW, Lee S, Fang LT,
Choi H, Ray R, Kang HC, Mao JH, Jablons D and Kim IJ: Gremlin is
overexpressed in lung adenocarcinoma and increases cell growth and
proliferation in normal lung cells. PLoS One. 7:e422642012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Seoane J: Gremlins sabotage the mechanisms
of cancer stem cell differentiation. Cancer Cell. 25:716–717. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yan K, Wu Q, Yan DH, Lee CH, Rahim N,
Tritschler I, DeVecchio J, Kalady MF, Hjelmeland AB and Rich JN:
Glioma cancer stem cells secrete Gremlin 1 to promote their
maintenance within the tumor hierarchy. Genes Dev. 28:1085–1100.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Curley MD, Therrien VA, Cummings CL,
Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden
DT, Rueda BR, et al: CD133 expression defines a tumor initiating
cell population in primary human ovarian cancer. Stem Cells.
27:2875–2883. 2009.PubMed/NCBI
|
|
30
|
Zhang S, Balch C, Chan MW, Lai HC, Matei
D, Schilder JM, Yan PS, Huang TH and Nephew KP: Identification and
characterization of ovarian cancer-initiating cells from primary
human tumors. Cancer Res. 68:4311–4320. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Friel AM, Sergent PA, Patnaude C, Szotek
PP, Oliva E, Scadden DT, Seiden MV, Foster R and Rueda BR:
Functional analyses of the cancer stem cell-like properties of
human endometrial tumor initiating cells. Cell Cycle. 7:242–249.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu SY and Zheng PS: High aldehyde
dehydrogenase activity identifies cancer stem cells in human
cervical cancer. Oncotarget. 4:2462–2475. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bortolomai I, Canevari S, Facetti I, De
Cecco L, Castellano G, Zacchetti A, Alison MR and Miotti S: Tumor
initiating cells: Development and critical characterization of a
model derived from the A431 carcinoma cell line forming spheres in
suspension. Cell Cycle. 9:1194–1206. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
López J, Valdez-Morales FJ,
Benítez-Bribiesca L, Cerbón M and Carrancá AG: Normal and cancer
stem cells of the human female reproductive system. Reprod Biol
Endocrinol. 11:532013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Maddox J, Shakya A, South S, Shelton D,
Andersen JN, Chidester S, Kang J, Gligorich KM, Jones DA, Spangrude
GJ, et al: Transcription factor Oct1 is a somatic and cancer stem
cell determinant. PLoS Genet. 8:e10030482012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yao T, Wu Z, Liu Y, Rao Q and Lin Z:
Aldehyde dehydrogenase 1 (ALDH1) positivity correlates with poor
prognosis in cervical cancer. J Int Med Res. 42:1038–1042. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Namkoong H, Shin SM, Kim HK, Ha SA, Cho
GW, Hur SY, Kim TE and Kim JW: The bone morphogenetic protein
antagonist gremlin 1 is overexpressed in human cancers and
interacts with YWHAH protein. BMC Cancer. 6:742006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu CY, Chao TK, Su PH, Lee HY, Shih YL,
Su HY, Chu TY, Yu MH, Lin YW and Lai HC: Characterization of LMX-1A
as a metastasis suppressor in cervical cancer. J Pathol.
219:222–231. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tsuchida R, Osawa T, Wang F, Nishii R, Das
B, Tsuchida S, Muramatsu M, Takahashi T, Inoue T, Wada Y, et al:
BMP4/Thrombospondin-1 loop paracrinically inhibits tumor
angiogenesis and suppresses the growth of solid tumors. Oncogene.
33:3803–3811. 2014. View Article : Google Scholar
|
|
40
|
Cassar L, Li H, Pinto AR, Nicholls C,
Bayne S and Liu JP: Bone morphogenetic protein-7 inhibits
telomerase activity, telomere maintenance, and cervical tumor
growth. Cancer Res. 68:9157–9166. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mitola S, Ravelli C, Moroni E, Salvi V,
Leali D, Ballmer-Hofer K, Zammataro L and Presta M: Gremlin is a
novel agonist of the major proangiogenic receptor VEGFR2. Blood.
116:3677–3680. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fotinos A, Nagarajan N, Martins AS, Fritz
DT, Garsetti D, Lee AT, Hong CC and Rogers MB: Bone morphogenetic
protein-focused strategies to induce cytotoxicity in lung cancer
cells. Anticancer Res. 34:2095–2104. 2014.PubMed/NCBI
|
|
43
|
Sanvitale CE, Kerr G, Chaikuad A, Ramel
MC, Mohedas AH, Reichert S, Wang Y, Triffitt JT, Cuny GD, Yu PB, et
al: A new class of small molecule inhibitor of BMP signaling. PLoS
One. 8:e627212013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Vogt J, Traynor R and Sapkota GP: The
specificities of small molecule inhibitors of the TGFß and BMP
pathways. Cell Signal. 23:1831–1842. 2011. View Article : Google Scholar : PubMed/NCBI
|
